Advertisement
Advertisement
LCTX
Lineage Cell Therapeutics, Inc.
1.03
USDSponsored
0.00
0.00%
Sep 18, 15:58 UTC -4
Closed
After-Market
1.04
+0.01
+0.97%
LCTX Earnings Reports
Positive Surprise Ratio
LCTX beat 24 of 43 last estimates.
56%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.09M
/-$0.03
Implied change from Q2 26 (Revenue/ EPS)
+2.41%
/-400.00%
Implied change from Q3 25 (Revenue/ EPS)
-70.26%
/-76.92%
Lineage Cell Therapeutics, Inc. earnings per share and revenue
On Aug 06, 2026, LCTX reported earnings of 0.01 USD per share (EPS) for Q2 26, beating the estimate of -0.02 USD, resulting in a 134.60% surprise. Revenue reached 1.07 million, compared to an expected 1.56 million, with a -31.54% difference. The market reacted with a -2.65% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.03 USD, with revenue projected to reach 1.09 million USD, implying an decrease of -400.00% EPS, and increase of 2.41% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Lineage Cell Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Lineage Cell Therapeutics, Inc. reported EPS of $0.01, beating estimates by 134.6%, and revenue of $1.07M, -31.54% below expectations.
How did the market react to Lineage Cell Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved down -2.65%, changed from $1.13 before the earnings release to $1.10 the day after.
When is Lineage Cell Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Lineage Cell Therapeutics, Inc.'s next earnings report?
Based on 7
analysts, Lineage Cell Therapeutics, Inc. is expected to report EPS of -$0.03 and revenue of $1.09M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.